Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK V416L |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BTK V416L | diffuse large B-cell lymphoma | resistant | Pirtobrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK V416L demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 35196427). | 35196427 | |
| BTK V416L | chronic lymphocytic leukemia | predicted - resistant | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with chronic lymphocytic leukemia who previously responded to Jaypirca (pirtobrutinib) treatment was found to have acquired a BTK V416L upon disease progression (PMID: 35196427). | 35196427 | |
| BTK V416L | diffuse large B-cell lymphoma | sensitive | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Imbruvica (ibrutinib) treatment inhibited phosphorylation of Btk and decreased viability of a diffuse large B-cell lymphoma cell line expressing BTK V416L in culture (PMID: 35196427). | 35196427 | |
| BTK V416L | diffuse large B-cell lymphoma | resistant | Fenebrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK V416L demonstrated resistance to Fenebrutinib (GDC-0853) in culture (PMID: 35196427). | 35196427 | |
| BTK V416L | diffuse large B-cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK V416L demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). | 35196427 | |
| BTK V416L | diffuse large B-cell lymphoma | sensitive | ARQ 531 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 531 treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK V416L in culture (PMID: 35196427). | 35196427 | |
| BTK V416L | diffuse large B-cell lymphoma | predicted - sensitive | NX-5948 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK V416L in culture (Cancer Res (2023) 83 (7_Supplement): 2850). | detail... | |
| BTK V416L | mantle cell lymphoma | resistant | RN486 | Preclinical - Cell culture | Actionable | In a preclinical study, a mantle cell lymphoma cell line developed resistance to RN486 after prolonged exposure in culture, and was subsequently found to have acquired BTK V416L (PMID: 36661329). | 36661329 | |
| BTK V416L | mantle cell lymphoma | sensitive | ARQ 531 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 531 inhibited viability of a mantle cell lymphoma cell line harboring BTK V416L in culture (PMID: 36661329). | 36661329 | |
| BTK V416L | diffuse large B-cell lymphoma | sensitive | NX-2127 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-2127 inhibited viability of a diffuse large B-cell lymphoma cell line expressing BTK V416L in culture (PMID: 38301010). | 38301010 | |
| BTK V416L | diffuse large B-cell lymphoma | resistant | Acalabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK V416L demonstrated resistance to Calquence (acalabrutinib) in culture (PMID: 38301010). | 38301010 | |
| BTK V416L | diffuse large B-cell lymphoma | resistant | Pirtobrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK V416L demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 38301010). | 38301010 | |
| BTK V416L | lymphoma | predicted - sensitive | DZD8586 | Preclinical - Cell culture | Actionable | In a preclinical study, DZD8586 inhibited proliferation of lymphoma cells expressing BTK V416L in culture (Blood (2023) 142 (Supplement 1): 2822). | detail... |